Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs in R&D
Published in: Drugs in R&D 1/2017

Open Access 01-03-2017 | Original Research Article

Baseline Characteristics and Changes in Bone Mineral Density T-Scores of Bulgarian Women with Postmenopausal Osteoporosis Receiving Denosumab in Routine Clinical Practice

Authors: Mihail Boyanov, Alexander Shinkov, Emi Psachoulia, Michele Intorcia, Reneta Petkova

Published in: Drugs in R&D | Issue 1/2017

Login to get access

Abstract

Background

Postmenopausal osteoporosis (PMO) is common among women over 50 years of age and is associated with an increased risk of fracture. Bone-targeted agents, such as denosumab, can reduce fracture risk in patients with PMO.

Objective

The aim was to describe baseline characteristics and changes in bone mineral density (BMD) T-scores among women with PMO receiving denosumab in Bulgaria.

Methods

This multicenter chart review included women with PMO receiving denosumab for ≥1 year in Bulgaria (October 2011–August 2013). Participants were required to have a baseline BMD T-score of ≤−2.5 standard deviations (SDs) at one or more skeletal sites.

Results

Overall, 222 women were included. The mean (SD) age at denosumab initiation was 64.2 (8.5) years; 26.6% reported a previous osteoporotic fracture and 6.8% a previous hip fracture. Only half of those reporting a previous fracture (49.2%) had received prior osteoporosis therapy. At baseline, mean (SD) BMD T-scores were lumbar spine −3.2 SD (0.6 SD), total hip −2.3 SD (0.8 SD), and femoral neck −2.7 SD (0.7 SD). After 1 year of denosumab treatment, scores increased significantly at all three sites, reaching −2.7 SD (0.6 SD), −2.1 SD (0.9 SD), and −2.4 SD (0.7 SD), respectively (all p < 0.0001 vs. baseline). No serious adverse drug reactions were identified.

Conclusion

Denosumab is usually prescribed in women with PMO at high fracture risk. In the patients who were persistent with treatment at 1 year, denosumab was well tolerated and effective at increasing BMD T-scores at several skeletal sites.
Literature
1.
2.
Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1–2):136.CrossRefPubMedPubMedCentral
3.
Borissova AM, Rashkov R, Boyanov M, et al. Femoral neck bone mineral density and 10-year absolute fracture risk in a national representative sample of Bulgarian women aged 50 years and older. Arch Osteoporos. 2011;6(1–2):189–95.CrossRefPubMed
4.
Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12(12):989–95.CrossRefPubMed
5.
Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med. 1997;103(2a):3S–8S.CrossRefPubMed
6.
Svedbom A, Hernlund E, Ivergard M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8(1–2):137.CrossRefPubMedPubMedCentral
7.
Gallacher SJ, Gallagher AP, McQuillian C, et al. The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures. Osteoporos Int. 2007;18(2):185–92.CrossRefPubMed
8.
Teede HJ, Renouf DA, Jayasuriya IA, et al. STOP fracture study: southern health osteoporotic fracture screening project. Int Med J. 2012;42(5):e74–9.CrossRef
9.
10.
Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.CrossRefPubMed
11.
Kostenuik PJ, Smith SY, Jolette J, et al. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone. 2011;49(2):151–61.CrossRefPubMed
12.
Ominsky MS, Stouch B, Schroeder J, et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone. 2011;49(2):162–73.CrossRefPubMed
13.
McClung MR, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res Off J Am Soc Bone Miner Res. 2012;27(1):211–8.CrossRef
14.
Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metabol. 2011;96(6):1727–36.CrossRef
15.
Bone HG, Brandi ML, Brown JP, et al. Ten years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension trial American Society for Bone and Mineral Research 2015 Annual Meeting, 9–12 October, Seattle, USA 2015.
16.
17.
Silverman SL, Siris E, Kendler DL, et al. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int. 2014;26(1):361–72.CrossRefPubMedPubMedCentral
18.
Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122(2 Suppl):S3–13.CrossRefPubMed
19.
Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res Off J Am Soc Bone Miner Res. 2009;24(1):153–61.CrossRef
20.
McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821–31.CrossRefPubMed
21.
Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375–82.CrossRefPubMed
22.
Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23–57.CrossRefPubMed
23.
Papapoulos S, Lippuner K, Roux C, et al. Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extension. Osteoporos Int. 2015;24(Suppl 2):Abstr OC21.
24.
Jennings LA, Auerbach AD, Maselli J, et al. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc. 2010;58(4):650–7.CrossRefPubMedPubMedCentral
25.
Kung AW, Fan T, Xu L, et al. Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens Health. 2013;13:7.CrossRefPubMedPubMedCentral
26.
McGowan B, Bennett K, Casey MC, et al. Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and 2008. Irish J Med Sci. 2013;182(4):601–8.CrossRefPubMed
27.
Teede HJ, Jayasuriya IA, Gilfillan CP. Fracture prevention strategies in patients presenting to Australian hospitals with minimal-trauma fractures: a major treatment gap. Int Med J. 2007;37(10):674–9.CrossRef
28.
Munson JC, Bynum JW, Bell J, et al. Patterns of prescription drug use before and after fragility fracture. JAMA Int Med. 2016;176(10):1531–8.CrossRef
29.
30.
Hiligsmann M, Ben Sedrine W, Bruyere O, et al. Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. Eur J Public Health. 2015;25:20–5.CrossRefPubMed
31.
Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337(10):670–6.CrossRefPubMed
32.
33.
Papapoulos S, Roux C, Bone HG, et al. Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the FREEDOM extension. Ann Rhem Dis. 2015;74(Suppl 2).
34.
Papapoulos S, Roux C, Bone HG, et al. Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the FREEDOM extension. Osteoporos Int. 2015;26 (Suppl 1):Abstr OC4.
35.
Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26:2479–89.CrossRefPubMedPubMedCentral
Metadata
Title
Baseline Characteristics and Changes in Bone Mineral Density T-Scores of Bulgarian Women with Postmenopausal Osteoporosis Receiving Denosumab in Routine Clinical Practice
Authors
Mihail Boyanov
Alexander Shinkov
Emi Psachoulia
Michele Intorcia
Reneta Petkova
Publication date
01-03-2017
Publisher
Springer International Publishing
Published in
Drugs in R&D / Issue 1/2017
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI
https://doi.org/10.1007/s40268-016-0159-3

Other articles of this Issue 1/2017

Drugs in R&D 1/2017 Go to the issue

short communication

Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events

Original Research Article

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates

Review Article

A Review of Clinical Outcomes Associated with Two Meropenem Dosing Strategies

Therapy in Practice

Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report

Original Research Article

Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data

Current Opinion

Drug Exposure and the Risk of Microscopic Colitis: A Critical Update